Despite Attacks, Strokes, Vision problems, Men’s Sex Dysfunction Drugs are Best Sellers

Side-Effects-of-ViagraThe global erectile dysfunction drugs market size was valued at over $4.39 billion in 2014. Key drivers of the market include an increase in patient awareness and education levels and growing base of geriatric population, according to Grand View Research, Inc.

However, reported side effects from the existing drugs are negatively affecting the industry growth. Availability of cost-effective counterfeit drugs is further expected to decrease the valuation of the branded erectile dysfunction drugs, according to Grandview, a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco.

Litigation against Viagra has been consolidated in US District Court in Minnesota in multidistrict litigation docket MDL 2691.  Sr. Judge Paul A. Magnuson Judicial Panel on Multidistrict Litigation (JPMDL) on Dec. 29 denied a joint request by Pfizer Inc. and Viagra plaintiffs to place a motion for a skin cancer multidistrict litigation on the panel’s Jan. 28 agenda (In Re: Viagra Products Liability Litigation, MDL Docket No. 2691, JPMDL). The panel’s next hearing in March.

Heart attacks, strokes, vision problems

Does your law firm have a mass tort case in active litigation? Kindly send your press releases directly to attorney Larry Bodine, Editor, Mass Tort Nexus.

Since its release in 1998, the erectile dysfunction (ED) drug, Viagra brought in billions of dollars for drug giant Pfizer.  Men who suffered heart attacks, strokes, vision problems and hearing troubles filed lawsuits against the drug maker. In 2005, the U.S. Food and Drug Administration ordered that warnings about vision loss be added to the drug’s label.

Government reforms and public awareness initiatives in developing regions of Asia Pacific and Latin America are expected to drive market growth during the forecast period. Economic development, healthcare infrastructure establishment, and increasing target population are estimated to provide potential growth platforms for this industry in these regions.

Novel molecule combinations and drug delivery techniques such as the use of creams and pellets that show better efficacy and performance are expected to become an opportunity for the erectile dysfunction drugs industry.

North America erectile dysfunction drugs market, by product, 2012-2022, (USD Million)

Viagra is top-selling drug worldwide.North America erectile dysfunction drugs market

The main line of drugs for erectile dysfunction treatment includes:

  • Vitaros
  • Zydena
  • Stendra
  • Levitra
  • Cialis
  • Viagra.

Viagra (sildenafil citrate) is one of the most widely distributed products worldwide. Viagra’s primary competitors are estimated to be Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG.

Key players of this market include Apricus Biosciences Inc., Bayer AG, Cristalia Dong-A Pharmaceutical Co. Ltd., Produtos Quimicos Farmaceuticos Ltd., Eli Lilly and Company, Pfizer, Inc., S.K. Chemicals Co. Ltd., Meda Pharmaceuticals, Inc., and Vivus, Inc. The industry for branded erectile dysfunction drugs is consolidated with key players involved in intense competition and rivalry.

Pfizer, Inc. accounted for the largest share at over 40.0% in 2012. However, the company’s market share is likely to decline over the forecast period owing to the patent expiry of Viagra in 2019. Generics are expected to boost industrial growth. In addition, post-patent expiration, mergers, acquisitions and collaborations activities, and geographic expansion are expected to keep industry rivalry at higher levels over the forecast period.

Larry Bodine

Attorney Larry Bodine is Editor of Mass Tort Nexus, and the Editor of The National Trial Lawyers. He is the former Editor in Chief of and the American Bar Association Journal. He is a cum laude graduate of both Seton Hall University Law School and Amherst College.

Leave a Reply